Jan 10, 2022 / 08:00PM GMT
Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
Good afternoon. I'm Robbie Marcus, the med tech analyst at JPMorgan. I'm very happy to host my next session with Zimmer Biomet. I have the CEO, Bryan Hanson; and the CFO, Suky Upadhyay. I think I was close there. Sorry, Suky. So we're going to diverge a little bit from the format we had for some of the other sessions. We're going to do 20 minutes of Q&A that allows Zimmer Biomet to highlight some of the really key topics today, and then we're going to move into 20 minutes of a little less formal Q&A. Please feel free to submit questions or e-mail me and I can do my best to get to all of them.
Questions and Answers:
Robert Justin Marcus - JPMorgan Chase & Co, Research Division - AnalystBut Bryan, Suky maybe to kick it off, Bryan, you've been at Zimmer Biomet for 4 years now. You've undergone this really big transformation process. Where do you sit now in the total process for Zimmer Biomet?
Bryan C. Hanson - Zimmer Biomet Holdings, Inc. -